UNSPSC 51273105: Hydroxydione sodium succinate

This classification denotes an anesthetic agent with the molecular formula C25H35O6.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53J8I8O5EW, chemically known as 21-hydroxypregnane-3,20-dione sodium hemisuccinate but more generally known as hydroxydione sodium, which bears US NIH Compound Identifier 5868. European Medicines Agency schedules Hydroxydione sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08078MIG.

UNSPSC 51273105 Hydroxydione sodium succinate is a Commodity code that in practice describes pharmaceutical products and related health-supply procurement by state and local governments, though the recent opportunities block shows limited direct alignment with the specific chemical compound named. State and local governments soliciting under this code purchase a range of pharmaceuticals, over-the-counter products, and emergency health supplies through both direct procurement and cooperative purchasing arrangements. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving state and local facilities. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent recent buyers, with MMCAP serving multiple states including Oregon through its cooperative purchasing vehicle.

Recent activity spans Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, requiring electronic bidding through the county's e-Procurement Portal and compliance with E-Verify and federal clean-air and water-pollution-control requirements. The Texas Health and Human Services Commission released RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed as preliminary market intelligence to inform future formal RFP development around direct contracting models outside traditional pharmacy benefit manager and wholesaler arrangements. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, requiring vendor certification to cGMP and Drug Supply Chain Security Act standards and relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026.